Cargando…

Unique volatolomic signatures of TP53 and KRAS in lung cells

BACKGROUND: Volatile organic compounds (VOCs) are potential biomarkers for cancer detection in breath, but it is unclear if they reflect specific mutations. To test this, we have compared human bronchial epithelial cell (HBEC) cell lines carrying the KRAS(V12) mutation, knockdown of TP53 or both wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, M P A, Barash, O, Jeries, R, Peled, N, Ilouze, M, Hyde, R, Marcus, M W, Field, J K, Haick, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453850/
https://www.ncbi.nlm.nih.gov/pubmed/25051409
http://dx.doi.org/10.1038/bjc.2014.411
_version_ 1782374515571949568
author Davies, M P A
Barash, O
Jeries, R
Peled, N
Ilouze, M
Hyde, R
Marcus, M W
Field, J K
Haick, H
author_facet Davies, M P A
Barash, O
Jeries, R
Peled, N
Ilouze, M
Hyde, R
Marcus, M W
Field, J K
Haick, H
author_sort Davies, M P A
collection PubMed
description BACKGROUND: Volatile organic compounds (VOCs) are potential biomarkers for cancer detection in breath, but it is unclear if they reflect specific mutations. To test this, we have compared human bronchial epithelial cell (HBEC) cell lines carrying the KRAS(V12) mutation, knockdown of TP53 or both with parental HBEC cells. METHODS: VOC from headspace above cultured cells were collected by passive sampling and analysed by thermal desorption gas chromatography mass spectrometry (TD-GC–MS) or sensor array with discriminant factor analysis (DFA). RESULTS: In TD-GC–MS analysis, individual compounds had limited ability to discriminate between cell lines, but by applying DFA analysis combinations of 20 VOCs successfully discriminated between all cell types (accuracies 80–100%, with leave-one-out cross validation). Sensor array detection DFA demonstrated the ability to discriminate samples based on their cell type for all comparisons with accuracies varying between 77% and 93%. CONCLUSIONS: Our results demonstrate that minimal genetic changes in bronchial airway cells lead to detectable differences in levels of specific VOCs identified by TD-GC–MS or of patterns of VOCs identified by sensor array output. From the clinical aspect, these results suggest the possibility of breath analysis for detection of minimal genetic changes for earlier diagnosis or for genetic typing of lung cancers.
format Online
Article
Text
id pubmed-4453850
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44538502015-09-09 Unique volatolomic signatures of TP53 and KRAS in lung cells Davies, M P A Barash, O Jeries, R Peled, N Ilouze, M Hyde, R Marcus, M W Field, J K Haick, H Br J Cancer Molecular Diagnostics BACKGROUND: Volatile organic compounds (VOCs) are potential biomarkers for cancer detection in breath, but it is unclear if they reflect specific mutations. To test this, we have compared human bronchial epithelial cell (HBEC) cell lines carrying the KRAS(V12) mutation, knockdown of TP53 or both with parental HBEC cells. METHODS: VOC from headspace above cultured cells were collected by passive sampling and analysed by thermal desorption gas chromatography mass spectrometry (TD-GC–MS) or sensor array with discriminant factor analysis (DFA). RESULTS: In TD-GC–MS analysis, individual compounds had limited ability to discriminate between cell lines, but by applying DFA analysis combinations of 20 VOCs successfully discriminated between all cell types (accuracies 80–100%, with leave-one-out cross validation). Sensor array detection DFA demonstrated the ability to discriminate samples based on their cell type for all comparisons with accuracies varying between 77% and 93%. CONCLUSIONS: Our results demonstrate that minimal genetic changes in bronchial airway cells lead to detectable differences in levels of specific VOCs identified by TD-GC–MS or of patterns of VOCs identified by sensor array output. From the clinical aspect, these results suggest the possibility of breath analysis for detection of minimal genetic changes for earlier diagnosis or for genetic typing of lung cancers. Nature Publishing Group 2014-09-09 2014-07-22 /pmc/articles/PMC4453850/ /pubmed/25051409 http://dx.doi.org/10.1038/bjc.2014.411 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Davies, M P A
Barash, O
Jeries, R
Peled, N
Ilouze, M
Hyde, R
Marcus, M W
Field, J K
Haick, H
Unique volatolomic signatures of TP53 and KRAS in lung cells
title Unique volatolomic signatures of TP53 and KRAS in lung cells
title_full Unique volatolomic signatures of TP53 and KRAS in lung cells
title_fullStr Unique volatolomic signatures of TP53 and KRAS in lung cells
title_full_unstemmed Unique volatolomic signatures of TP53 and KRAS in lung cells
title_short Unique volatolomic signatures of TP53 and KRAS in lung cells
title_sort unique volatolomic signatures of tp53 and kras in lung cells
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453850/
https://www.ncbi.nlm.nih.gov/pubmed/25051409
http://dx.doi.org/10.1038/bjc.2014.411
work_keys_str_mv AT daviesmpa uniquevolatolomicsignaturesoftp53andkrasinlungcells
AT barasho uniquevolatolomicsignaturesoftp53andkrasinlungcells
AT jeriesr uniquevolatolomicsignaturesoftp53andkrasinlungcells
AT peledn uniquevolatolomicsignaturesoftp53andkrasinlungcells
AT ilouzem uniquevolatolomicsignaturesoftp53andkrasinlungcells
AT hyder uniquevolatolomicsignaturesoftp53andkrasinlungcells
AT marcusmw uniquevolatolomicsignaturesoftp53andkrasinlungcells
AT fieldjk uniquevolatolomicsignaturesoftp53andkrasinlungcells
AT haickh uniquevolatolomicsignaturesoftp53andkrasinlungcells